RGC Regencell Bioscience Holdings Ltd
AI brief AI-written, not reviewed by a person
Latest available figures show Regencell Bioscience’s stockholders’ equity at 13,349,365 USD as of 2026-06-30, with total assets of 14,729,559 USD and total liabilities of 1,380,194 USD. For the prior year period ending 2025-06-30, stockholders’ equity was 4,860,274 USD, assets 5,755,582 USD, and liabilities 895,308 USD; net income for the 12 months to 2026-06-30 is -11,701,941 USD versus -3,584,213 USD for the 12 months to 2025-06-30, and diluted EPS for the year to 2026-06-30 is -2.37 USD per share (vs -0.72 USD for 2025). Cash and equivalents declined from 59,413 USD in 2021-06-30 to 6,416,998 USD in 2022-06-30, with prior smaller balances in 2020–2019–2018; other liquidity-related metrics are not consistently provided across the cited filings.
- As of 2026-06-30, stockholders’ equity is 13,349,365 USD; in 2025-06-30 it was 4,860,274 USD, indicating year-over-year growth in equity according to the stockholders’ equity filing. [1]
- Total assets reported as 14,729,559 USD for 2026-06-30, compared with 5,755,582 USD for 2025-06-30. [1]
- Total liabilities reported as 1,380,194 USD for 2026-06-30, compared with 895,308 USD for 2025-06-30. [1]
- Net income (year) for the 12 months to 2026-06-30 is -11,701,941 USD, versus -3,584,213 USD for the 12 months to 2025-06-30. [1]
- Operating cash flow (year) for the 12 months to 2026-06-30 is -7,695,530 USD, versus -3,113,576 USD for the 12 months to 2025-06-30. [1]
- Operating income (year) for the 12 months to 2026-06-30 is -11,724,461 USD, versus -3,769,985 USD for the 12 months to 2025-06-30. [1]
- Shares outstanding at 2026-06-30 are 495,884,376; at 2025-06-30 they are 494,488,908. [1]
- Cash and equivalents data show 6,416,998 USD at 2022-06-30, with earlier balances 59,413 USD at 2021-06-30, 386,979 USD at 2020-06-30, 243,307 USD at 2019-06-30, and 153,303 USD at 2018-06-30. [1]
- Diluted EPS (year) for the 12 months to 2026-06-30 is -2.37 USD per share; for 2025-06-30 it is -0.72 USD per share. [1]
Written by OpenVibe.AI from the SEC numbers and filings on this page, not reviewed by a person. Informational only; not investment advice. Written from figures and filings up to (gpt-5-nano-2025-08-07).
Observations
| Metric | Value | Observed | Source | Retrieved | Freshness |
|---|---|---|---|---|---|
| Net income (year) (12 months to 2026-06-30) | -11,701,941 USD | sec-companyfacts | current | ||
| Operating income (year) (12 months to 2026-06-30) | -11,724,461 USD | sec-companyfacts | current | ||
| Diluted EPS (year) (12 months to 2026-06-30) | -2.37 USD/shares | sec-companyfacts | current | ||
| Operating cash flow (year) (12 months to 2026-06-30) | -7,695,530 USD | sec-companyfacts | current | ||
| Total assets (at 2026-06-30) | 14,729,559 USD | sec-companyfacts | current | ||
| Total liabilities (at 2026-06-30) | 1,380,194 USD | sec-companyfacts | current | ||
| Stockholders' equity (at 2026-06-30) | 13,349,365 USD | sec-companyfacts | current | ||
| Cash and equivalents (at 2022-06-30) | 6,416,998 USD | sec-companyfacts | current | ||
| Shares outstanding (at 2026-06-30) | 495,884,376 shares | sec-companyfacts | current |
Context
No reviewed context has been published for RGC. The observations and documents below are shown as their sources stated them.
Documents
Source freshness
| Source | Freshness | Last successful fetch | Stale after | Sources reports |
|---|---|---|---|---|
| SEC EDGAR: company financial facts (XBRL) sec-companyfacts | current | 10080 min | ok | |
| SEC EDGAR: latest XBRL filings sec-xbrl-filings | current | 45 min | healthy |
Watch this instrument
Sign in to add RGC to a private watchlist or to get an alert when a new document or observation arrives.
Machine-readable: RGC.json (the same data with every timestamp and source).
Information only — not investment advice; no trading here. OpenVibe.Trade holds no money or assets, takes no orders and gives no personal recommendations.